FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Patricia Landis

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Prostate

Geographic Areas

Baltimore

Procedures

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Jeffrey K Mullins; Alan W Partin; Hosne Begum; David Bonekamp; H Ballentine Carter; Jonathan I Epstein; Patricia Landis; Katarzyna J Macura
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance.
Jeong S Han; Patricia Landis; Stephen Lee; Adam D Toll; Ali Amin; H Ballentine Carter; Jonathan I Epstein
Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Jeffrey J Tosoian; Bruce J Trock; Robert W Veltri; H Ballentine Carter; Debra J Elliot; Jonathan I Epstein; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Stacy Loeb; Alan W Partin; Lori J Sokoll
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Patricia Landis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jeffrey K Mullins; Alan W Partin; Hosne Begum; David Bonekamp; H Ballentine Carter; Jonathan I Epstein; Patricia Landis; Katarzyna J Macura
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance.
BJU international 2013;111(7):1037-45.
2012: Jeong S Han; Patricia Landis; Stephen Lee; Adam D Toll; Ali Amin; H Ballentine Carter; Jonathan I Epstein
Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Urology 2012;80(4):883-8.
2012: Jeffrey J Tosoian; Bruce J Trock; Robert W Veltri; H Ballentine Carter; Debra J Elliot; Jonathan I Epstein; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Stacy Loeb; Alan W Partin; Lori J Sokoll
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
The Journal of urology 2012;188(4):1131-6.
2012: Ashley E Ross; Bruce J Trock; Patrick C Walsh; H Ballentine Carter; Zhaoyong Feng; Patricia Landis; Phillip M Pierorazio; Edward M Schaeffer
Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
BJU international 2012;110(5):651-7.
2011: Kenneth S Tseng; Fadi Brimo; Jonathan I Epstein; Patricia Landis; Alan W Partin; H Ballentine Carter
Repeat prostate biopsies predict location of index cancer in an active surveillance cohort.
BJU international 2011;108(9):1415-20.
2011: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2185-90.
2010: Kenneth S Tseng; Patricia Landis; Jonathan I Epstein; Bruce J Trock; H Ballentine Carter
Risk stratification of men choosing surveillance for low risk prostate cancer.
The Journal of urology 2010;183(5):1779-85.
2010: Jeffrey J Tosoian; Stacy Loeb; Anna Kettermann; Patricia Landis; Debra J Elliot; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Lori J Sokoll
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
The Journal of urology 2010;183(2):534-8.
2010: Sumit Isharwal; Danil V Makarov; H Ballentine Carter; Jonathan I Epstein; Alan W Partin; Patricia Landis; Cameron Marlow; Robert W Veltri
DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme.
BJU international 2010;105(3):329-33.
2009: Kazutoshi Fujita; Patricia Landis; Brian K McNeil; Christian P Pavlovich
Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.
The Journal of urology 2009;182(6):2664-9.
2009: Edward M Schaeffer; H Ballentine Carter; Anna Kettermann; Stacy Loeb; Luigi Ferrucci; Patricia Landis; Bruce J Trock; E Jeffrey Metter
Prostate specific antigen testing among the elderly--when to stop?
The Journal of urology 2009;181(4):1606-14; discussion 1613-4.
2008: Stacy Loeb; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter; H Ballentine Carter
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.
European urology 2008;54(5):1073-80.
2008: Danil V Makarov; Cameron Marlow; Jonathan I Epstein; M Craig Miller; Patricia Landis; Alan W Partin; H Ballentine Carter; Robert W Veltri
Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.
The Prostate 2008;68(2):183-9.
2007: H Ballentine Carter; Anna Kettermann; Christopher A Warlick; E Jeffrey Metter; Patricia Landis; Patrick C Walsh; Jonathan I Epstein
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
The Journal of urology 2007;178(6):2359-64; discussion 2364-5.
2007: H Ballentine Carter; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.
Urology 2007;70(4):685-90.
2006: H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; EDWARD WRIGHT; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
Journal of the National Cancer Institute 2006;98(21):1521-7.
2006: J Kellogg Parsons; H Ballentine Carter; Alan W Partin; B Gwen Windham; E Jeffrey Metter; Luigi Ferrucci; Patricia Landis; Elizabeth A Platz
Metabolic factors associated with benign prostatic hyperplasia.
The Journal of clinical endocrinology and metabolism 2006;91(7):2562-8.
2006: Christopher A Warlick; Bruce J Trock; Patricia Landis; Jonathan I Epstein; H Ballentine Carter
Delayed versus immediate surgical intervention and prostate cancer outcome.
Journal of the National Cancer Institute 2006;98(5):355-7.
2005: J Kellogg Parsons; H Ballentine Carter; Elizabeth A Platz; EDWARD WRIGHT; Patricia Landis; E Jeffrey Metter
Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(9):2257-60.
2005: Michael C Haffner; Patricia Landis; Christopher S Saigal; H Ballentine Carter; Stephen J Freedland
Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation.
Urology 2005;66(2):371-6.
2005: Sonja I Berndt; H Ballentine Carter; Patricia Landis; Judith Hallfrisch; Sabine Rohrmann; E Jeffrey Metter; Elizabeth A Platz
Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer.
Nutrition (Burbank, Los Angeles County, Calif.) 2005;21(6):686-90.
2005: Stephen J Freedland; Michael C Haffner; Patricia Landis; Christopher S Saigal; H Ballentine Carter
Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy.
Urology 2005;65(6):1131-6.
2005: H Ballentine Carter; Patricia Landis; EDWARD WRIGHT; J Kellogg Parsons; E Jeffrey Metter
Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?
The Journal of urology 2005;173(6):2040-3.
2005: Elizabeth A Platz; Sabine Rohrmann; Jay D Pearson; Maria Corrada; Douglas J Watson; Angelo M DeMarzo; Patricia Landis; E Jeffrey Metter; H Ballentine Carter
Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(2):390-6.
2004: H Ballentine Carter; E Jeffrey Metter; James Wright; Patricia Landis; Elizabeth A Platz; Patrick C Walsh
Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging.
Journal of the National Cancer Institute 2004;96(7):557-8.
2004: J Slade Hubbard; Sabine Rohrmann; Patricia Landis; E Jeffrey Metter; Denis C Muller; Reubin Andres; H Ballentine Carter; Elizabeth A Platz
Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging.
Urology 2004;63(2):253-8.
2003: Masood A Khan; H Ballentine Carter; Jonathan I Epstein; M Craig Miller; Patricia Landis; Patrick C Walsh; Alan W Partin; Robert W Veltri
Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
The Journal of urology 2003;170(6 Pt 1):2274-8.
2003: Lillian J Hsieh; H Ballentine Carter; Patricia Landis; Katherine L Tucker; E Jeffrey Metter; Craig J Newschaffer; Elizabeth A Platz
Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States).
Urology 2003;61(2):297-301.
2002: Sonja I Berndt; H Ballentine Carter; Patricia Landis; Katherine L Tucker; Lillian J Hsieh; E Jeffrey Metter; Elizabeth A Platz
Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging.
Urology 2002;60(6):1118-23.
2002: Junyong Fang; E Jeffrey Metter; Patricia Landis; H Ballentine Carter
PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.
Urology 2002;59(6):889-93; discussion 893-4.
2002: EDWARD WRIGHT; Junyong Fang; E Jeffrey Metter; Alan W Partin; Patricia Landis; Daniel W Chan; H Ballentine Carter
Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.
The Journal of urology 2002;167(6):2484-7; discussion 2487-8.
2002: H Ballentine Carter; Patrick C Walsh; Patricia Landis; Jonathan I Epstein
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
The Journal of urology 2002;167(3):1231-4.
2001: James D Brooks; E J Metter; Daniel W Chan; Lori J Sokoll; Patricia Landis; William G Nelson; D Muller; Reubin Andres; H Ballentine Carter
Plasma selenium level before diagnosis and the risk of prostate cancer development.
The Journal of urology 2001;166(6):2034-8.
2001: J Fang; E Jeffrey Metter; Patricia Landis; Daniel W Chan; C H Morrell; H Ballentine Carter
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging.
Urology 2001;58(3):411-6.
2001: H Ballentine Carter; Patricia Landis; Jonathan I Epstein; Patrick C Walsh
Expectant management of prostate cancer with curative intent.
European urology 2001;39 Suppl 4():24.
2000: S Mitchell Harman; E Jeffrey Metter; Marc R Blackman; Patricia Landis; H Ballentine Carter
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.
The Journal of clinical endocrinology and metabolism 2000;85(11):4258-65.
2000: M R Feneley; Patricia Landis; I Simon; E J Metter; C H Morrell; H Ballentine Carter; Patrick C Walsh
Today men with prostate cancer have larger prostates.
Urology 2000;56(5):839-42.
1999: H Ballentine Carter; Patricia Landis; E Jeffrey Metter; Lee A Fleisher; Jay D Pearson
Prostate-specific antigen testing of older men.
Journal of the National Cancer Institute 1999;91(20):1733-7.
1999: A M Williams; I Simon; Patricia Landis; C Moser; W Christens-Barry; H Ballentine Carter; E Jeffrey Metter; Alan W Partin
Prostatic growth rate determined from MRI data: age-related longitudinal changes.
Journal of andrology 1999;20(4):474-80.
1997: Jay D Pearson; Christopher H Morrell; Larry J Brant; Patricia Landis; Jerome L Fleg
Age-associated changes in blood pressure in a longitudinal study of healthy men and women.
The journals of gerontology. Series A, Biological sciences and medical sciences 1997;52(3):M177-83.
1997: H Ballentine Carter; Alan W Partin; A A Luderer; E Jeffrey Metter; Patricia Landis; Daniel W Chan; J L Fozard; Jay D Pearson
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis.
Urology 1997;49(3):379-84.
1995: Jeffrey A Cadeddu; Jay D Pearson; BR Lee; Patricia Landis; Alan W Partin; Jonathan I Epstein; H Ballentine Carter
Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.
Urology 1995;45(5):795-800.
1994: Alan W Partin; Jay D Pearson; Patricia Landis; H Ballentine Carter; Charles R Pound; J Quentin Clemens; Jonathan I Epstein; Patrick C Walsh
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
Urology 1994;43(5):649-59.
1994: Jay D Pearson; Christopher H Morrell; Patricia Landis; H Ballentine Carter; Larry J Brant
Mixed-effects regression models for studying the natural history of prostate disease.
Statistics in medicine 1994;13(5-7):587-601.